Kenvue Inc. (NYSE:KVUE) Receives $25.33 Average PT from Brokerages

Kenvue Inc. (NYSE:KVUE - Get Free Report) has received an average recommendation of "Hold" from the twelve analysts that are presently covering the firm, MarketBeat reports. Seven investment analysts have rated the stock with a hold recommendation and five have given a buy recommendation to the company. The average 12-month price objective among brokers that have covered the stock in the last year is $25.33.

Several research analysts recently issued reports on the stock. Redburn Atlantic initiated coverage on shares of Kenvue in a research note on Thursday, April 10th. They set a "neutral" rating and a $23.50 target price on the stock. Royal Bank of Canada reiterated a "sector perform" rating and set a $24.00 target price on shares of Kenvue in a research note on Monday, February 3rd. Evercore ISI initiated coverage on shares of Kenvue in a research report on Monday, March 24th. They issued an "in-line" rating and a $25.00 price target on the stock. Canaccord Genuity Group increased their price objective on Kenvue from $24.00 to $29.00 and gave the stock a "buy" rating in a research report on Wednesday, March 5th. Finally, Piper Sandler increased their price target on shares of Kenvue from $24.00 to $27.00 and gave the company an "overweight" rating in a research report on Monday, February 24th.

Institutional Trading of Kenvue

A number of institutional investors and hedge funds have recently bought and sold shares of the business. Geneos Wealth Management Inc. purchased a new position in shares of Kenvue during the fourth quarter worth approximately $29,000. SRS Capital Advisors Inc. lifted its position in Kenvue by 67.4% during the fourth quarter. SRS Capital Advisors Inc. now owns 1,418 shares of the company's stock valued at $30,000 after buying an additional 571 shares in the last quarter. Pittenger & Anderson Inc. acquired a new position in shares of Kenvue during the first quarter worth $30,000. TruNorth Capital Management LLC acquired a new stake in Kenvue in the first quarter valued at $36,000. Finally, Truvestments Capital LLC acquired a new stake in shares of Kenvue during the 1st quarter worth approximately $37,000. 97.64% of the stock is currently owned by hedge funds and other institutional investors.

Kenvue Stock Performance

Shares of KVUE stock traded up $0.10 on Friday, reaching $23.65. The stock had a trading volume of 3,331,270 shares, compared to its average volume of 16,279,814. The company has a quick ratio of 0.69, a current ratio of 1.00 and a debt-to-equity ratio of 0.66. The firm's 50-day moving average is $23.25 and its two-hundred day moving average is $22.64. The firm has a market capitalization of $45.37 billion, a price-to-earnings ratio of 44.58, a P/E/G ratio of 2.62 and a beta of 1.02. Kenvue has a 12 month low of $17.67 and a 12 month high of $25.17.

Kenvue (NYSE:KVUE - Get Free Report) last announced its quarterly earnings data on Thursday, May 8th. The company reported $0.24 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.23 by $0.01. The business had revenue of $3.74 billion for the quarter, compared to analysts' expectations of $3.69 billion. Kenvue had a net margin of 6.66% and a return on equity of 20.97%. The firm's quarterly revenue was down 3.9% compared to the same quarter last year. During the same period last year, the firm posted $0.28 earnings per share. On average, research analysts expect that Kenvue will post 1.14 EPS for the current fiscal year.

Kenvue Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Wednesday, May 28th. Shareholders of record on Wednesday, May 14th were paid a $0.205 dividend. This represents a $0.82 dividend on an annualized basis and a yield of 3.47%. The ex-dividend date of this dividend was Wednesday, May 14th. Kenvue's dividend payout ratio (DPR) is 149.09%.

Kenvue Company Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.